This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

COC and cardiovascular disease (CVD) risk

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Arterial thromboembolic disease

Current use of CHC (combined hormonal contraception) is associated with a very small increased risk of myocardial infarction (MI) and ischaemic stroke that appears to be greater with higher doses of estrogen in COC.

Women should be informed that current use of CHC is associated with an increased risk of MI and ischaemic stroke but that that these events are still extremely uncommon in CHC users.

Use of CHC by women with significant additional risk factors for arterial disease should be strongly cautioned or avoided

Reference:

  • FSRH (July 2019). Combined Hormonal Contraception

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.